Skip to main content

Animations

MJFF Publications

831 - 840 of 6082 Results
Title
Year
  • Year
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • 2023
  • Summary Details
    OPEN
    Title: Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
    Journal Name: Science Advances
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc, cc-by-nc
    DOI - Digital Object Identifier: 10.1126/sciadv.adi8716
    Citation Count: 78
  • Summary Details
    OPEN
    Title: In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker
    Journal Name: International Journal of Molecular Sciences
    Publisher: MDPI AG
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3390/ijms242216445
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Hippocampal glial inflammatory markers are differentially altered in a novel mouse model of perimenopausal cerebral amyloid angiopathy
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2023.1280218
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA‐PD Study
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1002/mds.29611
    Citation Count: 12
  • Summary Details
    OPEN
    Title: Evaluating the Utility of REVEL and CADD for Interpreting Variants in Amyotrophic Lateral Sclerosis Genes
    Journal Name: Human Mutation
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1155/2023/8620557
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease mouse model
    Journal Name: Nature Communications
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1038/s41467-023-42876-1
    Citation Count: 36
  • Summary Details
    OPEN
    Title: A genetic and transcriptomic assessment of the KTN1 gene in Parkinson’s disease risk
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2023.11.001
    Citation Count: 0
  • Summary Details
    OPEN
    Title: Targeting sleep and the circadian system as a novel treatment strategy for Parkinson’s disease
    Journal Name: Journal of Neurology
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s00415-023-12073-7
    Citation Count: 8
  • Summary Details
    OPEN
    Title: Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's
    Journal Name: European Journal of Neuroscience
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by, cc-by, cc-by
    DOI - Digital Object Identifier: 10.1111/ejn.16180
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Ethnoracial differences for caregiving burden in Parkinson’s disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2023.105927
    Best OA location URL:
    Citation Count: 1
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.